Chris Shibutani
Stock Analyst at Goldman Sachs
(2.97)
# 1,453
Out of 5,133 analysts
96
Total ratings
54%
Success rate
8.45%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $46.02 | +117.30% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $7.51 | -60.03% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $15.97 | -6.07% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $29.15 | +9.78% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $107.19 | +27.81% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $20.47 | +61.21% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $476.86 | -36.67% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $40.36 | +26.36% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $213.65 | -27.45% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $12.60 | -68.25% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $8.43 | +137.25% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $1,077.19 | -32.88% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $18.31 | +42.00% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $132.26 | +15.68% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $220.75 | -21.63% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $36.58 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $55.92 | +23.39% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $19.51 | -33.37% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $119.95 | -80.83% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $13.86 | +260.75% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $74.13 | -29.85% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $25.15 | +138.57% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $10.46 | +72.08% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $10.44 | +62.84% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.59 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.04 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.24 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $46.02
Upside: +117.30%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $7.51
Upside: -60.03%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $15.97
Upside: -6.07%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $29.15
Upside: +9.78%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $107.19
Upside: +27.81%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $20.47
Upside: +61.21%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $476.86
Upside: -36.67%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $40.36
Upside: +26.36%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $213.65
Upside: -27.45%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $12.60
Upside: -68.25%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $8.43
Upside: +137.25%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $1,077.19
Upside: -32.88%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $18.31
Upside: +42.00%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $132.26
Upside: +15.68%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $220.75
Upside: -21.63%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $36.58
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $55.92
Upside: +23.39%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $19.51
Upside: -33.37%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $119.95
Upside: -80.83%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $13.86
Upside: +260.75%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $74.13
Upside: -29.85%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $25.15
Upside: +138.57%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $10.46
Upside: +72.08%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $10.44
Upside: +62.84%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.59
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $7.04
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $6.24
Upside: -